To improve patients’ lives
Acting on this mission has propelled us to become a global biopharmaceutical leader with a focus on innovation and specialty care.
Our passion drives our commitment to patients living with difficult-to-treat diseases, and we put them first. Because patients are our priority, we help them through our expertise in oncology, neuroscience, and rare diseases.
With a team of over 90 across our headquarters in Mississauga, Ontario and our research & development facility in Montreal, Quebec, our Canadian operation brings together the best of both worlds: the agility of a start-up, backed by the resources and experience of a global biopharmaceutical company. Ipsen Canada is also a member of Innovative Medicines Canada (IMC).
We bring medicines to patients with the strength of nearly 6,000 employees across the globe, including innovators in our key therapeutic areas.Download our annual report
Patients are the heart of our science
That’s why we apply the rigor of data to everything we do, whether we’re working in neurology, oncology, or rare diseases—we strive to leave no patient behind. We’ve shaped our research and development pipeline with a goal of launching at least one new drug or meaningful indication every year.
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at helping patients with neuroendocrine tumors, advanced kidney cancer (renal cell carcinoma) and liver cancer (hepatocellular carcinoma).
People suffering from neurological disorders are in need of treatments, and we’ve become a global leader in creating them through the research, development, manufacturing and commercialization of neurotoxins to help treat certain types of spasticity in adults and children two years and older, and cervical dystonia in adults.
We continue to evolve and grow our research efforts in the area of rare and ultra-rare diseases. Given the limited understanding of these diseases, we are committed to addressing patient needs, from supporting diagnosis to treatment with specific investment in pituitary pathologies, growth disorders, and ultra-rare bone diseases, including fibrodysplasia ossificans progressiva, commonly known as FOP.
Clinical trials can lead to medical outcomes that help improve lives, and we thank all of our patients who make this critical research possible through their participation in trials. If you would like to learn more about enrolling in a study, visit Health Canada’s Clinical Trials Database.
Responsibility is our policy
Our passion for helping patients extends beyond the office walls
We endeavor to have a responsible and sustainable impact on patients, society, and the environment. We are people who aim to make a difference in our communities, both inside and outside of the workplace. We match donations from employees to support nonprofit organizations through Ipsen Gives Back, our internal matching gifts program.
Every year our employees in Canada participate in a Day of Service, focusing on—and working side-by-side with—organizations that help lift up our local communities.
And throughout the year, we participate in other events to raise awareness of the diseases that impact
Meet our leadership team
General Manager, Ipsen Canada
Senior Director, Finance and Supply Chain
Director, Business Insights and Analytics
Head of Medical Affairs, Canada
Director, Human Resources, Ipsen Canada and Global R&D
Business Ethics Director
Senior Business Unit Director, Oncology
Director of Regulatory Affairs, Reimbursement & Value Access
Executive Director, Clinical Operations and Montreal Site Head
Business Unit Head, Neuroscience and Rare Disease